Creation of a long-acting rilpivirine prodrug nanoformulation
Antiretroviral therapy requires lifelong daily dosing to attain viral suppression, restore
immune function, and improve quality of life. As a treatment alternative, long-acting (LA) …
immune function, and improve quality of life. As a treatment alternative, long-acting (LA) …
Long-acting cabotegravir and rilpivirine: innovation, new challenges, and opportunities
JM Llibre, DAR Kuritzkes - Clinical Infectious Diseases, 2023 - academic.oup.com
Cabotegravir (an integrase strand transfer inhibitor [INSTI] that is structurally similar to
dolutegravir) and rilpivirine (a nonnucleoside reverse transcriptase inhibitor [NNRTI]) …
dolutegravir) and rilpivirine (a nonnucleoside reverse transcriptase inhibitor [NNRTI]) …
Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
A once every eight-week cabotegravir (CAB) long-acting parenteral is more effective than
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …
daily oral emtricitabine and tenofovir disoproxil fumarate in preventing human …
[HTML][HTML] Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …
treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly …
A year-long extended release nanoformulated cabotegravir prodrug
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
monthly. However, dosing volumes, injection site reactions and health-care oversight are …
Long-acting antiretroviral therapy
Long-acting antiretroviral therapy | Nature Materials Skip to main content Thank you for visiting
nature.com. You are using a browser version with limited support for CSS. To obtain the best …
nature.com. You are using a browser version with limited support for CSS. To obtain the best …
Design strategies for long-acting anti-HIV pharmaceuticals
Y Sang, L Ding, C Zhuang, F Chen - Current Opinion in Pharmacology, 2020 - Elsevier
Highlights•Long-acting (LA) antiretroviral formulations could help to prevent transmission of
HIV, and improve adherence.•Cabenuva, a simplified LA combination antiretroviral therapy …
HIV, and improve adherence.•Cabenuva, a simplified LA combination antiretroviral therapy …
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation
G van′ t Klooster, E Hoeben, H Borghys… - Antimicrobial agents …, 2010 - Am Soc Microbiol
The next-generation human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse
transcriptase inhibitor rilpivirine (TMC278) was administered in rats and dogs as single …
transcriptase inhibitor rilpivirine (TMC278) was administered in rats and dogs as single …
Long-acting antiviral agents for HIV treatment
DA Margolis, M Boffito - Current Opinion in HIV and AIDS, 2015 - journals.lww.com
Phase II studies evaluating the coadministration of rilpivirine and cabotegravir
intramuscularly to HIV-infected individuals with an undetectable viral load are currently …
intramuscularly to HIV-infected individuals with an undetectable viral load are currently …
Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques
JE McMillan, A Szlachetka, T Zhou, B Morsey… - Aids, 2019 - journals.lww.com
Long-acting antiretrovirals can improve therapy and prevention for HIV-1 infection. Current
long-acting cabotegravir (CAB LAP) can be administered every other month. Previously, we …
long-acting cabotegravir (CAB LAP) can be administered every other month. Previously, we …